Literature DB >> 18221994

Irreversible sensorineural hearing loss due to Imatinib.

Venkata Satya Suresh Attili1, P P Bapsy, G Anupama, D Lokanatha.   

Abstract

OBJECTIVE: We report probably the first case of bilateral irreversible sensorineural hearing loss caused by Imatinib.
METHOD: A review of the world literature, concerning Imatinib toxicity is presented.
RESULTS: We report a case of bilateral irreversible sensorineural hearing loss, in a 19-year-old male patient of chronic myeloid leukemia after 3 months of Imatinib therapy. Audiometric evaluation documented the findings.
CONCLUSION: To the best of our knowledge, this is the first case report of Imatinib induced sensorineural hearing loss. This case indicates that treating oncologists should keep in mind that this drug too can produce ototoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221994     DOI: 10.1016/j.leukres.2007.11.039

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  Screening for chemicals that affect hair cell death and survival in the zebrafish lateral line.

Authors:  Henry Ou; Julian A Simon; Edwin W Rubel; David W Raible
Journal:  Hear Res       Date:  2012-01-31       Impact factor: 3.208

2.  Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line.

Authors:  Yoshinobu Hirose; Julian A Simon; Henry C Ou
Journal:  J Assoc Res Otolaryngol       Date:  2011-07-06

Review 3.  Oxymorphone insufflation associated with acute sensorineural hearing loss: case files of the University of Massachusetts medical toxicology fellowship.

Authors:  Katherine L Boyle; Christopher D Rosenbaum
Journal:  J Med Toxicol       Date:  2013-06

4.  Audio Vestibular Status in CML Patients on Imatinib Mesylate with Review of Literature.

Authors:  Rijuneeta Gupta; Uday Yanamandra; Bhumika Gupta; Naresh K Panda; Subhash Varma; Anu Nagarkar; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2015-10-28       Impact factor: 0.900

5.  Evaluation of Nivolumab for Ototoxic Effects: An Animal Study in Rats.

Authors:  İsmail Güler; İhsan Kuzucu; Deniz Baklacı; Rauf Oğuzhan Kum; Esra Özhamam Uçaryılmaz; Müge Özcan
Journal:  J Int Adv Otol       Date:  2020-08       Impact factor: 1.017

6.  Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study.

Authors:  Adem Bora; Kasım Durmuş; Hatice Terzi; Emine Elif Altuntaş
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

7.  Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST).

Authors:  Komal Wasif; Nawal Wasif; Muhammad W Saif
Journal:  Cureus       Date:  2016-10-26

8.  Cell death-inducing cytotoxicity in truncated KCNQ4 variants associated with DFNA2 hearing loss.

Authors:  Takashi Kojima; Koichiro Wasano; Satoe Takahashi; Kazuaki Homma
Journal:  Dis Model Mech       Date:  2021-11-26       Impact factor: 5.758

9.  Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.

Authors:  Allison B Coffin; Emily Dale; Emilee Doppenberg; Forrest Fearington; Tamasen Hayward; Jordan Hill; Olivia Molano
Journal:  Front Cell Neurosci       Date:  2022-08-24       Impact factor: 6.147

10.  Permanent sensorineural deafness in a patient with chronic myelogenous leukemia secondary to intracranial hemorrhage.

Authors:  Sakshi Kapur; Michael Wax; Levin Miles; Adnan Hussain
Journal:  Case Rep Hematol       Date:  2013-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.